辛伐他汀对急性心肌梗死患者基质金属蛋白酶和高敏C反应蛋白的影响

目的：探讨辛伐他汀对急性心肌梗死患者血浆高敏C反应蛋白和基质金属蛋白酶-9的影响。方法：60例急性心肌梗死患者随机分为两组,常规治疗组和辛伐他汀治疗组,治疗前后分别测定血浆高敏C反应蛋白和基质金属蛋白酶-9的浓度,并与对照组比较。结果：急性心肌梗死患者血浆高敏C反应蛋白和基质金属蛋白酶-9的测定值高于健康对照组（P〈0.05）;辛伐他汀治疗组治疗后血浆高敏C反应蛋白和基质金属蛋白酶-9的测定值分别低于治疗前水平（P〈0.05）。结论：辛伐他汀通过抗炎等机制对防治急性心肌梗死患者早期动脉粥样硬化及稳定斑块起着重要的作用。

Effect of simvastatin on matrix metalloproteinase-9 and high sensitive C reactive protein in patients with acute myocardial infarction

Objective To investigate the effect of simvastatin on serum levels of matrix metalloproteinase-9 and high sensitive C reactive protein in the patients with acute myocardial infarction.Methods Sixty patients with acute myocardial infarction were randomly divided into two groups.Control group(30 cases) was given routine therapy;the treatment group was given routine therapy and 40 mg simvastatin once a day for 2 weeks.The serum levels of matrix metalloproteinase-9 and high sensitive C reactive protein were measured before and after therapy with ELISA method,which were compared with those in control group.Results The serum levels of matrix metalloproteinase-9 and high sensitive C reactive protein in the patients with acute myocardial infarction were significantly higher than those in control group(P<0.05).The serum levels of matrix metalloproteinase-9 and high sensitive C reactive protein significantly lowered after two weeks of therapy in the simvastatin treatment group.Conclusion The serum levels of matrix metalloproteinase-9 and high sensitive C reactive protein are increased in patients with acute myocardial infarction and early simvastatin intervention may decrease the serum levels of matrix metalloproteinase-9 and high sensitive C reactive protein.Early intensive simvastatin treatment may yield more significant benefits in the patients with acute myocardial infarction.